image
Harrow Health, Inc. 8.625% Senior Notes due 2026 HROWL
Healthcare - Medical - Pharmaceuticals - NASDAQ - US
Watchlist
$ 25.08
0.08 %
$ 857 M
Market Cap
None
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HROWL stock under the worst case scenario is HIDDEN Compared to the current market price of 25.1 USD, Harrow Health, Inc. 8.625% Senior Notes due 2026 is HIDDEN

HROWL Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HROWL stock under the base case scenario is HIDDEN Compared to the current market price of 25.1 USD, Harrow Health, Inc. 8.625% Senior Notes due 2026 is HIDDEN

HROWL Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HROWL stock under the best case scenario is HIDDEN Compared to the current market price of 25.1 USD, Harrow Health, Inc. 8.625% Senior Notes due 2026 is HIDDEN

HROWL Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart HROWL

image
1M 1%
6M 3%
1Y 10%
3Y 30%
5Y --%
All
$25.2$25.2$25.0$25.0$24.8$24.8$24.6$24.6$24.4$24.4$24.2$24.2$24.0$24.0$23.8$23.8Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
200 REVENUE
153321507.15%
Growth Rates
1Year 153321507.15%
3Years 13917.34%
5Years 1980.86%
7Years 858.92%
10Years 542.69%
8.82 OPERATING INCOME
2046867649.42%
Growth Rates
1Year 2046867649.42%
3Years 31335.20%
5Years 2710.61%
7Years 587.41%
10Years 292.58%
(17.5) NET INCOME
-71611058.90%
Growth Rates
1Year -71611058.90%
3Years -9801.67%
5Years -4157.27%
7Years -659.56%
10Years -320.48%
-22.2 M OPERATING CASH FLOW
-578.18%
Growth Rates
1Year -578.18%
3Years -75.10%
5Years -89.40%
7Years -14.13%
10Years -12.15%
(33.2) INVESTING CASH FLOW
-21739229.94%
Growth Rates
1Year -21739229.94%
3Years -12007.38%
5Years -2728.14%
7Years -1093.57%
10Years -470.34%
28.5 FINANCING CASH FLOW
22546688.06%
Growth Rates
1Year 22546688.06%
3Years 8114.33%
5Years 2994.10%
7Years 824.83%
10Years 485.93%
66.8 M REVENUE
35.68%
Growth Rates
1Year 153321507.15%
3Years 13917.34%
5Years 1980.86%
7Years 858.92%
10Years 542.69%
12.9 M OPERATING INCOME
876.46%
Growth Rates
1Year 2046867649.42%
3Years 31335.20%
5Years 2710.61%
7Years 587.41%
10Years 292.58%
6.78 M NET INCOME
260.59%
Growth Rates
1Year -71611058.90%
3Years -9801.67%
5Years -4157.27%
7Years -659.56%
10Years -320.48%
-17.8 M OPERATING CASH FLOW
-602.47%
Growth Rates
1Year -578.18%
3Years -75.10%
5Years -89.40%
7Years -14.13%
10Years -12.15%
-37.6 M INVESTING CASH FLOW
-6191.46%
Growth Rates
1Year -21739229.94%
3Years -12007.38%
5Years -2728.14%
7Years -1093.57%
10Years -470.34%
30 M FINANCING CASH FLOW
4258.81%
Growth Rates
1Year 22546688.06%
3Years 8114.33%
5Years 2994.10%
7Years 824.83%
10Years 485.93%
Balance Sheet Harrow Health, Inc. 8.625% Senior Notes due 2026
image
Current Assets 190
Cash & Short-Term Investments 47.2
Receivables 116
Other Current Assets 26
Non-Current Assets 199
Long-Term Investments 0
PP&E 12.3 M
Other Non-Current Assets 199
12.15 %29.92 %6.69 %51.24 %Total Assets$389.0t
Current Liabilities 91.3
Accounts Payable 38.8 M
Short-Term Debt 497 K
Other Current Liabilities 91.3
Non-Current Liabilities 228
Long-Term Debt 228 M
Other Non-Current Liabilities 228
28.57 %71.43 %Total Liabilities$319.7t
EFFICIENCY
Earnings Waterfall Harrow Health, Inc. 8.625% Senior Notes due 2026
image
Revenue 200
Cost Of Revenue 49.2
Gross Profit 150
Operating Expenses 141
Operating Income 8.82
Other Expenses 26.3
Net Income (17.5)
200t200t150t150t100t100t50t50t00(50t)(50t)200t(49t)150t(141t)9t(26t)(17t)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.33% GROSS MARGIN
75.33%
Averages
1Year 75.33%
3Years 72.08%
5Years 72.30%
7Years 69.83%
10Years 63.55%
4.42% OPERATING MARGIN
4.42%
Averages
1Year 4.42%
3Years 0.93%
5Years -0.19%
7Years -2.08%
10Years -29.22%
-0.00% NET MARGIN
-0.00%
Averages
1Year -0.00%
3Years -11.55%
5Years -13.30%
7Years -5.17%
10Years -34.03%
-0.00% ROE
-0.00%
Averages
1Year -0.00%
3Years -28.74%
5Years -51.67%
7Years -29.80%
10Years 18.43%
-0.00% ROA
-0.00%
Averages
1Year -0.00%
3Years -5.60%
5Years -8.21%
7Years -2.27%
10Years -24.85%
2.94% ROIC
2.94%
Averages
1Year 2.94%
3Years 0.61%
5Years -0.33%
7Years -7.41%
10Years -36.11%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Harrow Health, Inc. 8.625% Senior Notes due 2026
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income (17.5)
Depreciation & Amortization 14.5 M
Capital Expenditures -38.7 M
Stock-Based Compensation 17.6
Change in Working Capital -44.6 M
Others 42.4
Free Cash Flow -60.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Harrow Health, Inc. 8.625% Senior Notes due 2026
image
HROWL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.539 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.500002.500002.000002.000001.500001.500001.000001.000000.500000.500000.000000.000000.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539062.160.539062.160.539062.160.539061.620.002021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
6. Ownership
Insider Ownership Harrow Health, Inc. 8.625% Senior Notes due 2026
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile Summary

Harrow Health, Inc. 8.625% Senior Notes due 2026 HROWL

image
COUNTRY US
INDUSTRY Medical - Pharmaceuticals
MARKET CAP $ 857 M
Dividend Yield 0.00%
Description Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Contact Nashville, DE, http://www.harrowinc.com
IPO Date May 7, 2021
Employees 217
Officers